Benefits Of Avandia, Actos Outweigh Risks – EMEA
EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.
EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.